Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 4,000 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW – Get Rating) VP Daveen Chopra sold 4,000 shares of the business’s stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $78.00, for a total transaction of $312,000.00. Following the transaction, the vice president now directly owns 18,911 shares of the company’s stock, valued at approximately $1,475,058. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Daveen Chopra also recently made the following trade(s):

• On Thursday, December 15th, Daveen Chopra sold 4,000 shares of Edwards Lifesciences stock. The shares were sold at an average price of $74.80, for a total transaction of $299,200.00.
• On Tuesday, November 15th, Daveen Chopra sold 4,000 shares of Edwards Lifesciences stock. The shares were sold at an average price of $74.18, for a total transaction of $296,720.00.

Edwards Lifesciences Price Performance

NYSE EW opened at $78.86 on Wednesday. The stock’s 50-day moving average price is $75.01 and its two-hundred day moving average price is $85.73. The company has a current ratio of 3.83, a quick ratio of 3.00 and a debt-to-equity ratio of 0.10. The company has a market cap of $48.76 billion, a PE ratio of 33.99, a PEG ratio of 2.72 and a beta of 1.03. Edwards Lifesciences Co. has a 1 year low of $67.13 and a 1 year high of $131.10.

Edwards Lifesciences (NYSE:EW – Get Rating) last posted its quarterly earnings data on Thursday, October 27th. The medical research company reported $0.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.01). The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.34 billion. Edwards Lifesciences had a return on equity of 24.75% and a net margin of 27.20%. On average, analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on EW shares. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Edwards Lifesciences from $113.00 to $83.00 in a report on Friday, October 28th. Cowen reduced their price objective on shares of Edwards Lifesciences from $125.00 to $100.00 in a report on Friday, October 28th. Wolfe Research downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Thursday, December 1st. Jefferies Financial Group assumed coverage on shares of Edwards Lifesciences in a report on Wednesday, October 12th. They issued a “buy” rating and a $110.00 price objective for the company. Finally, Mizuho reduced their price objective on shares of Edwards Lifesciences from $100.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, December 7th. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $99.68.

Hedge Funds Weigh In On Edwards Lifesciences

A number of large investors have recently made changes to their positions in the business. Diversified Trust Co increased its holdings in shares of Edwards Lifesciences by 29.3% in the 4th quarter. Diversified Trust Co now owns 31,810 shares of the medical research company’s stock valued at $2,373,000 after purchasing an additional 7,209 shares during the period. Arthur M. Cohen & Associates LLC increased its holdings in shares of Edwards Lifesciences by 1.5% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 20,738 shares of the medical research company’s stock valued at $1,547,000 after purchasing an additional 300 shares during the period. Beese Fulmer Investment Management Inc. increased its holdings in shares of Edwards Lifesciences by 1.5% in the 4th quarter. Beese Fulmer Investment Management Inc. now owns 117,124 shares of the medical research company’s stock valued at $8,739,000 after purchasing an additional 1,713 shares during the period. Capital Advisors Inc. OK increased its holdings in shares of Edwards Lifesciences by 1.4% in the 4th quarter. Capital Advisors Inc. OK now owns 11,024 shares of the medical research company’s stock valued at $823,000 after purchasing an additional 155 shares during the period. Finally, Ronald Blue Trust Inc. increased its holdings in shares of Edwards Lifesciences by 50.7% in the 4th quarter. Ronald Blue Trust Inc. now owns 3,753 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 1,263 shares during the period. Institutional investors and hedge funds own 80.35% of the company’s stock.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.